Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings
- PMID: 10704428
- DOI: 10.2741/matalon
Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings
Abstract
Canavan disease is a severe progressive leukodystrophy characterized by swelling and spongy degeneration of the white matter of the brain. It is an autosomal recessive disease found more frequently among Ashkenazi Jews. The clinical features are those of severe mental retardation with inability to gain developmental milestones. Hypotonia, head lag and macrocephaly are characteristic of Canavan disease and become apparent after 5-6 months of age. Massive excretion in the urine of N-acetylaspartic acid is the biochemical marker for Canavan disease, which is caused by deficiency of the enzyme aspartoacylase. This discovery allowed for accurate diagnosis of Canavan disease, while prior to that, a brain biopsy was needed. The gene for aspartoacylase has been cloned and two mutations predominate among Ashkenazi Jewish individuals with Canavan disease and account for more than 98% of the Ashkenazi Jewish patients. The mutations among other ethnic groups are more diverse. The carrier frequency for the two common mutations among Ashkenazi Jews was found to be surprisingly high, 1:37. Screening for carriers is now common practice for this population. A knock-out mouse for Canavan disease is being genetically engineered in our laboratory. The mouse model will allow for development of strategies for gene therapy.
Similar articles
-
Canavan disease: diagnosis and molecular analysis.Genet Test. 1997;1(1):21-5. doi: 10.1089/gte.1997.1.21. Genet Test. 1997. PMID: 10464621 Review.
-
Canavan disease: a monogenic trait with complex genomic interaction.Mol Genet Metab. 2003 Sep-Oct;80(1-2):74-80. doi: 10.1016/j.ymgme.2003.08.015. Mol Genet Metab. 2003. PMID: 14567959 Review.
-
Canavan disease: from spongy degeneration to molecular analysis.J Pediatr. 1995 Oct;127(4):511-7. doi: 10.1016/s0022-3476(95)70105-2. J Pediatr. 1995. PMID: 7562269 Review.
-
Molecular basis of Canavan's disease: from human to mouse.J Child Neurol. 2003 Sep;18(9):604-10. doi: 10.1177/08830738030180090601. J Child Neurol. 2003. PMID: 14572138 Review.
-
Canavan disease: biochemical and molecular studies.J Inherit Metab Dis. 1993;16(4):744-52. doi: 10.1007/BF00711906. J Inherit Metab Dis. 1993. PMID: 8412017 Review.
Cited by
-
N-acetylaspartic acid impairs enzymatic antioxidant defenses and enhances hydrogen peroxide concentration in rat brain.Metab Brain Dis. 2010 Jun;25(2):251-9. doi: 10.1007/s11011-010-9202-1. Epub 2010 May 1. Metab Brain Dis. 2010. PMID: 20437087
-
Microbial Neuraminidase Induces a Moderate and Transient Myelin Vacuolation Independent of Complement System Activation.Front Neurol. 2017 Mar 7;8:78. doi: 10.3389/fneur.2017.00078. eCollection 2017. Front Neurol. 2017. PMID: 28326060 Free PMC article.
-
Developing Hypoimmunogenic Human iPSC-Derived Oligodendrocyte Progenitor Cells as an Off-The-Shelf Cell Therapy for Myelin Disorders.Adv Sci (Weinh). 2023 Aug;10(23):e2206910. doi: 10.1002/advs.202206910. Epub 2023 Jun 4. Adv Sci (Weinh). 2023. PMID: 37271923 Free PMC article.
-
Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease.Exp Anim. 2024 Jul 9;73(3):347-356. doi: 10.1538/expanim.23-0089. Epub 2024 Mar 28. Exp Anim. 2024. PMID: 38538326 Free PMC article.
-
Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease.Cell Biosci. 2024 Apr 6;14(1):45. doi: 10.1186/s13578-024-01224-6. Cell Biosci. 2024. PMID: 38582917 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical